3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Not yet recruiting
1
Sponsor Class
NIH
2
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Cardiotoxicity
7
Neoplasms
3
Heart Failure
3
Breast Neoplasms
3
Cardiovascular Diseases
2
Ventricular Dysfunction, Left
1
Triple Negative Breast Neoplasms
1
Thoracic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Metabolic Syndrome
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Long QT Syndrome
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Diseases
1
Dyslipidemias
1
Colonic Neoplasms
1
Central Nervous System Neoplasms
1
Cardiomyopathies
1
Brugada Syndrome
1
Bone Marrow Diseases
1
Atrial Fibrillation
1
Arrhythmias, Cardiac
1
Interventions
Cyclophosphamide
184
fludarabine phosphate
162
fludarabine
128
Busulfan
116
Tacrolimus
109
Mycophenolic Acid
101
Whole-Body Irradiation
97
Antilymphocyte Serum
87
Peripheral Blood Stem Cell Transplantation
84
Azacitidine
82
Melphalan
81
Filgrastim
74
Cytarabine
74
Cyclosporine
72
Methotrexate
64
Decitabine
57
Granulocyte Colony-Stimulating Factor
51
Thiotepa
45
Radiotherapy
41
thymoglobulin
40
Stem Cell Transplantation
40
Cord Blood Stem Cell Transplantation
40
venetoclax
39
Clofarabine
35
Sirolimus
30
Methylprednisolone
30
Specimen Handling
27
Etoposide
24
Alemtuzumab
24
Biopsy
23
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Myelodysplastic Syndromes
×
Electrocardiography
×
Clear all
NCT07387354
2026-03-16
MDS
Thomas Jefferson University
Phase 1/2
Not yet recruiting
25 enrolled